Effect of mao-A and mao-B inhibitors in ganglia and nerve endings
Keywords:
clorgilina, deprenil, MAO-A y MAO-BAbstract
Se estudio el efecto de clorgilina y deprenil sobre la liberación y el metabolismo de 3H-noradrenalina (3H-NA) en elganglio superior (GCS) y en la membrana nictitante (MN) de gato. Nuestros resultados muestran que en el GCS,clorgilina y deprenil redujeron del mismo modo la formación de 3,4-dihidroxi-fenilglicol (DOPEG) mientras que enla MN la disminución del DOPEG fue mayor con clorgilina que con deprenil. En el GCS la monoaminooxidasa(MAO) A y B cataliza la deaminación de NA a 3H-DOPEG, a 3H-3,4-acido-dihidroximandílico (3H-DOMA) o a losmetabolitos 3H—O-metilados deaminados (3H-OMDA). En la MN la MAO-A presináptica cataliza la deaminaciónde NA principalmente a 3H-DOPEG, la MAO-B postsináptica a 3H-NMN y; la MAO-A y B a 3H-DOMA y 3H-OMDA.Downloads
References
Caramona M. and Osswald W. (1985). Effects of clorgyline and (-) deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein. Naunyn-Schmiedeberg’s Arch Pharmac., 328: 396-400.
Filinger E. (1986). In vitro metabolism of 3H-NA induced by pargyline in the superior cervical ganglion. Gen. Pharmac., 17: 709-710.
Filinger E. (1994a). In vitro release of 3H-noradrenaline by tyramine from the superior cervical ganglion and in the nictitating membrane of the cat. Gen Pharmac., 25: 1045-1049.
Filinger E. (1994b). Effect of a reserpine-like agent on the release and metabolism of 3H-NA in cell bodies and terminales. Gen Pharmac., 25: 1039-1043.
Filinger E. and Stefano F. (1981a). In vitro release of 3H-noradrenaline by amphetamine from the superior cervical ganglion of the cat. Acta Physiol. Latinoam., 31: 105-111.
Filinger E. and Stefano F. (1981b). MAO-A and MAO-B in the superior cervical ganglion and in the nictitating membrane of the cat. Gen. Pharmac., 12: 481-484.
Fowler C. and Tipton K. (1983). On the substrate specificities of the two forms of monoamine oxidase J. Pharm. Pharmac., 36: 111-115.
Fowler J., Volkow N., Wang G., Pappas N., Logan J., MacGregor R., Alexoff D., Wolf A., Warmer D., Cliento R. and Zezulkova I. (1998) Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J.Addict.Dis 17: 23-34
Graefe K., Stefano F. and Langer S. (1973). Preferential metabolism of (-)3H-norepinephrine through the deaminated glycol in the rat vas deferens. Biochem. Pharmac., 22: 1147-1160.
Jain M. (1977). Monoamine oxidase: examination of multiple forms. Life Sci., 20: 1925-1934.
Johnston J. (1968). Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmac., 17: 1285-1297.
Kamijo K., Usdin and Nagatsu T. (1982). Monoamine oxidase, basic and clinical frontiers. Excerpta Medica Int. Congr. Ser., 564: 1-378.
Knoll J. and Magyar K. (1972). Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmac., 5: 393-408.
Saura S., Nadal E., Van den Berg B., Vila M., Bombi J. and Mahy N. (1996). Localization of monoamine oxidases in human peripheral tissues. Life Sci., 59: 1341-1349.
Snedecor G. and Cochran W. (1967). Statistical Method, 6th Ed. The Iowa State University Press, Amcs, IA, U.S.A. Tipton K., Houslay M. and Mantle T. (1976). In Monoamine Oxidase and its Inhibition. pp. 5-31. Ciba Foundation
Symposium 39, Elsevier, Amsterdam, Netherlands. Uchida E. and Koelle G. (1984). Histochemical investigations of criteria for the distinction between monoamine oxidase A and B in various species. J. Histochem. Cytochem., 32: 667-673.
Verbeuren T. and Vanhoutte P. (1982). Deamination of released 3H-noradrenaline in the canine saphenous vein. Naunyn-Schmiedeberg’s Arch Pharmac., 318: 148-157.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).